Nuclear medicine is expected to make major advances in cancer diagnosis and therapy;
tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal …

Many patients with hepatocellular carcinoma (HCC) present with advanced disease, not
amenable to curative therapies such as surgery, transplantation or radiofrequency ablation …

One of the major limitations of current cancer therapy is the inability to deliver tumoricidal
agents throughout the entire tumor mass using traditional intravenous administration …

The purpose of our study was to evaluate the reproducibility of Modified Response
Evaluation Criteria in Solid Tumors (mRECIST) in hepatocellular carcinoma (HCC) lesions …

The repair and regeneration of peri-implant soft tissues is essential for the long-term clinical
successes of implants. Surface modification of implants using coatings is an effective …

Hepatocellular carcinoma is the most common primary liver cancer and it represents the
majority of cancer-related deaths in the world. More than 70% of patients present at an …

Radiation therapy is used as a primary treatment for inoperable tumors and in patients that
cannot or will not undergo surgery. Radioactive holmium-166 (166Ho) is a viable candidate …

Background Selective arterial radioembolisation of liver tumours has increased, because of
encouraging efficacy reports; however, therapeutic parameters used in external beam …

Optimal treatment planning for radioembolization of hepatic cancers produces sufficient
dose to tumors for control and dose to normal liver parenchyma that is below the threshold …

Patients with hepatocellular carcinoma (HCC) comply with an advanced disease and are not
eligible for radical therapy. In this distressed scenario new treatment options hold great …